MOUNTAIN VIEW, California (GenomeWeb) – Free from political pressures, Robert Califf, who on Jan. 20 stepped down as US Food and Drug Administration commissioner, candidly spoke at a conference yesterday about the need for greater oversight of laboratory-developed tests.

While a swathe of the lab industry would disagree, investors and drugmakers at the Personalized Medicine World Conference (PMWC) conceded that regulation isn't always a negative, and has, for example, spurred greater use of biomarkers in drug development to improve understanding of disease biology.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.